Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD
Study Details
Study Description
Brief Summary
This protocol allows for the treatment of pediatric patients, male and female, between the ages of 2 months and 17 years. Patients must have failed steroid treatment for Grade B-D acute GVHD.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
For the treatment of pediatric patients who have failed to respond to steroid treatment for acute graft-versus-host disease (GVHD). Failing steroid treatment for acute GVHD is defined as any Grade B-D (IBMTR grading) of acute GVHD that is not improving after at least 3 days of methylprednisolone (≥ 1 mg/kg/day) or equivalent.
Patients will be treated with Prochymal twice per week at a dose of 2 x 10^6 hematopoietic stem cells (hMSC)/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion criteria:
-
Patients must sign an informed consent form (ICF) before any protocol-related procedures, including any pre-treatment procedures, are performed.
-
Since patients being treated with Prochymal® under this protocol are under 18, a parental signature of informed consent will be required.
-
Patients must be 2 months to 17 years of age, inclusive.
-
Patients must have failed to respond to steroid treatment for Grades B-D acute GVHD • Failure to respond to steroid treatment for acute GVHD is defined as any Grade B-D acute GVHD that is not improving after at least 3 days of methylprednisolone (≥1 milligram per kilogram per day [mg/kg/day]) or equivalent.
Exclusion criteria:
-
Patient must not have a known allergy to bovine or porcine products.
-
Patient must not have received a transplant for a solid tumor disease.
-
Patients must not have evidence of a pulmonary infiltrate or diffuse alveolar hemorrhage and must be unlikely to require more than 2 liters (L) of oxygen via face mask or an estimated fraction of inspired oxygen (FiO2) of 28% via other delivery methods in order to sustain an O2 saturation of 92% during the next 3 days.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Phoenix Children's Hospital | Phoenix | Arizona | United States | 85016 |
2 | Children's Hospital of Orange County | Orange | California | United States | 92868 |
3 | UCSF | San Francisco | California | United States | 94143 |
4 | Children's National | Washington | District of Columbia | United States | 20010 |
5 | Nemours Children's Clinic | Jacksonville | Florida | United States | 32207 |
6 | University of Miami | Miami | Florida | United States | 33136 |
7 | Childrens Memorial | Chicago | Illinois | United States | 60614 |
8 | James Witcomb Riley Hosptial for Children | Indianapolis | Indiana | United States | 46202 |
9 | LSU Health Science Center/Children's Hospital | New Orleans | Louisiana | United States | 70118 |
10 | Wayne State University/Childrens' Hospital | Detroit | Michigan | United States | 48201 |
11 | Children's Mercy Hospital | Kansas City | Missouri | United States | 64108 |
12 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
13 | Hackensack University Medical Center | Hackensack | New Jersey | United States | 07601 |
14 | Columbia Medical Center | New York | New York | United States | 10032 |
15 | Memorial Sloan-Kettering Cancer Center | New York | New York | United States | 10065 |
16 | Levine Children's Hospital | Charlotte | North Carolina | United States | 28232 |
17 | Duke University Medical Center | Durham | North Carolina | United States | 27710 |
18 | Doernbecher Children's Hospital (OHSU) | Portland | Oregon | United States | 97239 |
19 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
20 | Vanderbilt Children's Hospital | Nashville | Tennessee | United States | 37232 |
21 | Texas Childrens Hospital | Houston | Texas | United States | 77030 |
22 | Methodist Childrens Hospital of South Texas | San Antonio | Texas | United States | 78229 |
23 | Massey Cancer Center | Richmond | Virginia | United States | 23298 |
24 | Medical College of Wisconsin | Milwaukee | Wisconsin | United States | 53226 |
25 | Alberta Children's Hospital | Calgary | Alberta | Canada | T3B 6A8 |
26 | Montreal Children's Hospital | Montreal | Quebec | Canada | H3H1P3 |
27 | CHU Sainte-Justine | Montreal | Quebec | Canada | H3T1C5 |
Sponsors and Collaborators
- Mesoblast, Inc.
Investigators
- Study Director: Mahboob Rahman, Mesoblast, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 275